DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 208056
NDA 208056 describes DEXILANT SOLUTAB, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are fifteen patents protecting this drug. Additional details are available on the DEXILANT SOLUTAB profile page.
The generic ingredient in DEXILANT SOLUTAB is dexlansoprazole. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.
The generic ingredient in DEXILANT SOLUTAB is dexlansoprazole. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.
Summary for 208056
| Tradename: | DEXILANT SOLUTAB |
| Applicant: | Takeda Pharms Usa |
| Ingredient: | dexlansoprazole |
| Patents: | 15 |
Medical Subject Heading (MeSH) Categories for 208056
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Strength | 30MG | ||||
| Approval Date: | Jan 26, 2016 | TE: | RLD: | Yes | |||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Nov 17, 2019 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Dec 15, 2020 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Jul 30, 2023 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Complete Access Available with Subscription
